Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Exelixis Inc EXEL

Healthcare Biotechnology
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved... see more

Recent & Breaking News (NDAQ:EXEL)

Exelixis Announces Results from Randomized Phase 2 Trial CABOSUN Demonstrate Cabozantinib Significantly Improved Progression-Free Survival versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma

Business Wire May 23, 2016

Exelixis to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 10

Business Wire May 5, 2016

Exelixis Announces First Quarter 2016 Financial Results and Provides Corporate Update

Business Wire May 4, 2016

Exelixis to Release First Quarter 2016 Financial Results on Wednesday, May 4, 2016

Business Wire April 26, 2016

Exelixis Announces FDA Approval of CABOMETYX(TM) (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Business Wire April 25, 2016

Exelixis-Discovered Compounds to Be Featured in 18 Presentations at 2016 ASCO Annual Meeting

Business Wire April 20, 2016

Exelixis to Present at Two Investor Conferences in March

Business Wire March 3, 2016

Exelixis Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update

Business Wire February 29, 2016

Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan

Business Wire February 29, 2016

Exelixis to Release Fourth Quarter and Full Year 2015 Financial Results on Monday, February 29, 2016

Business Wire February 15, 2016

Exelixis to Present at the Leerink Partners 5th Annual Global Healthcare Conference on February 10

Business Wire February 4, 2016

Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma

Business Wire February 1, 2016

Exelixis Announces European Medicines Agency Acceptance of Marketing Authorization Application for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

Business Wire January 28, 2016

Exelixis Announces U.S. FDA Deems New Drug Application Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

Business Wire January 28, 2016

Exelixis Submits Marketing Authorization Application in the European Union for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

Business Wire January 11, 2016

Exelixis Announces Positive Results From Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma to be Presented at ASCO 2016 Genitourinary Cancers Symposium

Business Wire January 4, 2016

Exelixis Completes Submission of New Drug Application for Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Business Wire December 23, 2015

Exelixis Announces European Commission Approval of COTELLIC(TM) (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma

Business Wire November 25, 2015

Exelixis Announces Presentation of Positive Overall Survival Results for COTELLIC(TM) in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma at Society for Melanoma Research 2015 International Congress

Business Wire November 21, 2015

Exelixis to Present at the Stifel 2015 Healthcare Conference on Tuesday, November 17

Business Wire November 12, 2015